We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

AB Sciex to Combine Eksigent Chromatography with Capillary Electrophoresis from Beckman

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

AB Sciex Pte. Ltd. announces the combination of its chromatography business with the capillary electrophoresis business from Beckman Coulter Life Sciences. 

This combination includes the transition of personnel as well as capillary electrophoresis (CE) technologies and resources from Beckman Coulter Life Sciences to AB Sciex ‒ two leading life science companies that are both owned by Danaher Corporation, a leader in science and technology.  This new alignment will lead to better serving customers while addressing analytical challenges with powerful scientific strategies that take advantage of complementary technologies.

“We are bringing together the best in CE with the best in nano LC and micro LC as a unified team to broaden the range of solutions available to our customers,” said Rainer Blair, President of AB Sciex.  “By integrating the Beckman Coulter CE team into the Sciex separations business, we will be able to take CE and our chromatography solutions to a whole new level.  We are committed to investing in our separations business for long-term success.”  

The Eksigent LC team of the Sciex separations business and the CE team of Beckman Coulter, a leader in benchtop capillary electrophoresis, will work together going forward to develop breakthrough, integrated applications that provide fast and efficient separations of drugs, drug metabolites, organic acids, amino acids, low molecular weight amines, peptides, nucleic acids and nucleosides.

The new alignment within the Sciex separations business will also unlock greater potential to extend technology leadership, synergies and market presence.  This will contribute to the advancement of biologics, clinical research and academic research for biological applications.

Among the synergies is the combination of CE technology and mass spectrometry (MS) technology.  CE-MS allows researchers to expand the range of analytes detected while improving overall assay sensitivity.  The selectivity of CE in front-end separation further enables the characterization of intact proteins, their isoforms, cleaved fragments and complexes.  CE-MS provides information that is complementary to nano LC for proteomics research.  

By the end of Q3, the Sciex separations business will manage both the standalone Beckman Coulter CE products and the integrated CE-MS technology.  The CE products will continue to be branded ‘Beckman Coulter.’  The separations business will also continue to manage all chromatography products, including Eksigent nano LC and micro LC systems, chips, software and columns.